Physician profile
John Wickman
NPI 1871513739
$1,598.35
in general payments reported to CMS, 2019-2025
19 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $67.27 · 2021: $629 · 2022: $331 · 2023: $126 · 2024: $101 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.03 | 2021-2024 | Ubrelvy |
| Merck Sharp & Dohme LLC | $126.79 | 2019 | |
| Esperion Therapeutics, INC. | $119.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.66 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $96.21 | 2023-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $90.35 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $76.67 | 2019-2025 | Jardiance, Zepbound |
| Depuy Synthes Sales INC. | $44.91 | 2022 | |
| Allergan, INC. | $38.16 | 2020 | |
| Boston Scientific Corporation | $35.78 | 2019-2023 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $30.91 | 2021 | |
| Novo Nordisk INC | $24.84 | 2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $21.37 | 2025 | Dexcom G6 Transmitter |
| Vifor Pharma, INC. | $18.45 | 2021 | |
| Hikma Pharmaceuticals USA | $17.04 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.93 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.19 | 2025 | Zoryve |
| Apria Healthcare LLC | $13.70 | 2021 | |
| Horizon Therapeutics Plc | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.